Vaccine adjuvant technology by SEPPIC

The role of vaccine adjuvants in the immune response

Vaccine adjuvants (from the Latin adjuvare meaning “to help”) are substances that increase the intensity of the immune response after co-administration with an antigen. They are useful for enabling vaccines to induce strong and persistent immune responses, while reducing the vaccine dose and number of injections, and increasing the vaccine’s stability. Adjuvants for vaccines are used in the formulation of human and veterinary vaccines.

Categories of vaccine adjuvants

In human vaccination, only few adjuvant technologies are used in the formulation of vaccines on the market. Aluminum salts have been used for over a century. New technologies have been developed in recent decades, such as liposomes, purified Quillaja saponaria saponin, and squalene-type emulsions in water.

Veterinary vaccination uses a greater variety of adjuvant technologies, in particular aluminum salts, oil-in-water, water-in-oil or multiple emulsions, polymer dispersions, saponins, as well as other naturally occurring immunostimulants.

Vaccine adjuvants can have two mechanisms of action:

  • As vectors which, due to their physicochemical properties, simulate the presence of an infectious agent. These effectively present the antigen to cells of the immune system in order to facilitate its rapid absorption and improve the immune response. This is especially so with aluminum salts and emulsions.
  • As immunostimulants that specifically interact with receptors located on immune cells. This is the mechanism of action in Toll-Like Receptor (TLR) ligands, for example.

Several adjuvant technologies combine these two mechanisms to potentiate their effectiveness. It is also possible to combine two different types of adjuvants within the same vaccine.

Select a vaccine adjuvant

The use of an immunity adjuvant is considered from the outset of a vaccine development project, whether human or veterinary. In developing an inactivated or subunit vaccine, it is necessary to add an adjuvant to guarantee the effectiveness of the vaccine and the duration of the immunity conferred. For the development of a live attenuated or vectorized vaccine, the addition of an adjuvant is optional, but may reduce the antigenic load per vaccine dose.

An adjuvant is expected to be:

  • Effective and capable of inducing – in combination with the selected antigen – a strong immune response to protect the host from an infectious disease,
  • Well-tolerated so as not to cause a local or systemic reaction,
  • Compatible with the antigen in the formulation to allow the formulation of a stable and reproducible vaccine,
  • Easy to use, both for formulation with the antigen and for injection,
  • Reproducible in order to guarantee the same performance independently of the batch, and produced according to the quality benchmark required for the desired application.

There is no universal adjuvant that is suitable for all pathologies. The selection of an adjuvant for a vaccine project needs to integrate many criteria, in particular the type of vaccine (prophylactic or therapeutic), the mode of administration, the antigen technology, the immune orientation of the response sought for the pathology target, the duration of immunity sought, and, for animal health, the target animal species.

Seppic develops and offers various vaccine adjuvant technologies dedicated to human and animal health, in particular the oily and polymeric adjuvants of the MontanideTM range. Seppic has also developed the required expertise to select the most suitable adjuvant for each vaccine development project.

Continue reading about vaccine adjuvant and solutions by SEPPIC here

More on SEPPIC

You might also like